Alnylam Pharmaceuticals' Tax Provisions fell 516.75% to -$12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.5 million, marking a year-over-year decrease of 776.59%. This contributed to the annual value of -$99.2 million for FY2024, which is 1575.36% down from last year.
According to the latest figures from Q3 2025, Alnylam Pharmaceuticals' Tax Provisions is -$12.1 million, which was down 139.18% from $30.9 million recorded in Q2 2025.
In the past 5 years, Alnylam Pharmaceuticals' Tax Provisions registered a high of $30.9 million during Q2 2025, and its lowest value of -$110.2 million during Q4 2024.
Over the past 3 years, Alnylam Pharmaceuticals' median Tax Provisions value was $2.3 million (recorded in 2024), while the average stood at -$5.3 million.
In the last 5 years, Alnylam Pharmaceuticals' Tax Provisions skyrocketed by 13,091.30% in 2023 and then slumped by 60,315.85% in 2024.
Alnylam Pharmaceuticals' Tax Provisions (Quarterly) stood at -$1.8 million in 2021, then spiked by 125.62% to $472,000 in 2022, then crashed by 61.23% to $183,000 in 2023, then tumbled by 60,315.85% to -$110.2 million in 2024, then slumped by 516.75% to -$12.1 million in 2025.
Its Tax Provisions stands at -$12.1 million for Q3 2025, versus $30.9 million for Q2 2025 and $15.9 million for Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value